Search - tctmd.com

Displaying 221 - 240 of 344

Sort: Relevancy | Date

News Conference News SCAI 2018

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

L.A. McKeown

April 26, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

Shelley Wood

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

Caitlin E. Cox

February 23, 2018

Podcast TCTMD Talking Points

Switching Antiplatelet Therapy: New International Consensus

January 24, 2018

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

News Daily News

Higher Bleeding Risks, Radial Advantages Confirmed in Women With ACS Undergoing PCI: MATRIX Subanalysis

Yael L. Maxwell

January 03, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Daily News

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

L.A. McKeown

December 20, 2017

News Daily News

Radial Access Best for PCI Following Thrombolysis in STEMI

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Presentation TCT 2017

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Advertisement

ORBITA Continues to Surprise: 85% of Sham Arm Opted for PCI When Trial Ended

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

Switching Antiplatelet Therapy: New International Consensus

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Higher Bleeding Risks, Radial Advantages Confirmed in Women With ACS Undergoing PCI: MATRIX Subanalysis

The Biggest News of 2017: TCTMD’s Top 10

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

Radial Access Best for PCI Following Thrombolysis in STEMI

RE-DUAL PCI Findings Consistent Across Key Subgroups

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content